Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | PRNP | P04156 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155412 | 0.87 | PRNP (0.52) | MCL1KDM4EALDH1A1GPR35PRNP | |
| SCHEMBL3617512 | 0.87 | MCL1 (0.67) | MCL1KDM4EALDH1A1GPR35CASP6 | |
| SCHEMBL17182567 | 0.85 | PRNP (0.51) | MCL1KDM4EALDH1A1GPR35PRNP | |
| SCHEMBL31683105 | 0.83 | NPC1 (0.59) | MCL1KDM4EALDH1A1PRNPCASP6 | |
| SCHEMBL4655120 | 0.83 | MCL1 (0.71) | MCL1KDM4EALDH1A1GPR35KCNH2 | |
| SCHEMBL11286491 | 0.83 | TSHR (0.54) | MCL1KDM4EALDH1A1PRNPCASP6 | |
| SCHEMBL3500416 | 0.80 | HIF1A (0.57) | KDM4EALDH1A1PRNPKCNH2TSHR | |
| SCHEMBL4763051 | 0.80 | MCL1 (0.67) | MCL1KDM4EALDH1A1GPR35NPC1 | |
| SCHEMBL1385653 | 0.80 | MCL1 (1.00) | MCL1KDM4EALDH1A1GPR35KCNH2 | |
| SCHEMBL5193307 | 0.80 | MAPT (0.55) | MCL1KDM4EALDH1A1GPR35PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131893-B1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3131893-B1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3131893-A1 | POLYCYCLIC HERG ACTIVATORS | Novartis AG (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20160108025-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG | 2016-04-21 | — | — | US | disclosed |
| US-20160108025-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG | 2016-04-21 | — | — | US | disclosed |
| US-20160108025-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG | 2016-04-21 | — | — | US | disclosed |
| US-9255093-B2 | Polycyclic HERG activators | NOVARTIS AG (CH) | 2016-02-09 | — | — | US | disclosed |
| US-9255093-B2 | Polycyclic HERG activators | NOVARTIS AG (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150299181-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20150299181-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20150299181-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2015-10-22 | — | — | US | disclosed |
| WO-2015161052-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161052-A1 | POLYCYCLIC HERG ACTIVATORS | NOVARTIS AG (CH) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108025-A1 | POLYCYCLIC HERG ACTIVATORS | KCNH3, KCNH2, KCNJ11 | MCL1 1229/4885KDM4E 2010/4885ALDH1A1 1847/4885 |
| US-20150299181-A1 | POLYCYCLIC HERG ACTIVATORS | KCNH3, KCNH2, KCNJ11 | MCL1 1229/4885KDM4E 2010/4885ALDH1A1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.